Press Release

Freedom to choose leading multiplex immunofluorescence chemistries with ZEISS tissue multiplexing workflow

Bringing leading multiplex immunofluorescence chemistries together in one automated 8-channel imaging platform

18 September 2025

Jena, Germany | 18 September 2025 | ZEISS Research Microscopy Solutions

ZEISS is introducing an enhanced workflow with the ZEISS Axioscan 7 spatial biology automated slide scanner, with an integrated newly launched data analysis solution, now offering seamless compatibility with a broad range of established tissue multiplexing reagent chemistries.

The new workflow enables researchers and translational scientists to accelerate biomarker validation and clinical studies, driving faster impact for patients.

Broad compatibility with leading reagents

The system supports both DNA-barcoded multiplex immunofluorescence (mIF) and Tyramide Signal Amplification (TSA)-based chemistries, including leading solutions like: InSituPlex assay from Ultivue by Vizgen, SignalStar^® mIHC by Cell Signaling Technology, and StreptaClick^® TSA panels by Kromnigon. Researchers can also deploy a wide variety of fluorophores – spanning industry standards like OPAL^™ dyes as well as next-generation TSA dyes from Spatomics – to achieve robust, high-resolution imaging in 8-plex assays and beyond.

Integrated brightfield & fluorescence imaging

In addition to mIF, the system enables imaging of immunohistochemistry (IHC) and hematoxylin and eosin (H&E) slides within the same run. Scientists can now combine multiplex fluorescence and brightfield assays in a single, streamlined batch, simplifying laboratory workflows and enhancing data integration across assay modalities.

High-capacity, walk-away automation

Engineered for efficiency and throughput, the platform accommodates up to 100 slides per run and provides fully walk-away automation – from scanning to integrated image analytics with Mindpeak PhenoScout AI. This closed-loop approach reduces operator hands-on time while ensuring reproducible results across large-scale studies, regardless of the reagent choice.

Accelerating spatial biology workflows

“Consistency in imaging quality, automation, and analysis is critical – and can now be paired with the flexibility to select the reagent chemistry that best meets project needs”, said Michael Albiez, Head of ZEISS Research Microscopy Solutions. “With this platform, we deliver an open yet fully integrated solution that unifies mIF, IHC, and H&E imaging in one seamless workflow – empowering labs to move faster from sample to insight with confidence.”

Customers can prioritize the strengths of different reagent chemistries – sensitivity, panel flexibility, protocol duration or ease of use – without compromising workflow integration, imaging quality or throughput, ensuring unmatched flexibility in their research approach.

Press Contact Vybhav Sinha ZEISS Research Microscopy Solutions

About ZEISS

ZEISS is an internationally leading technology company in the optics and optoelectronics industry. The ZEISS Group generated annual revenue totaling around 11 billion euros in its four segments Industrial Quality & Research, Medical Technology, Consumer Markets and Semiconductor Manufacturing Technology (updated: 30 September 2024).

For its customers, ZEISS develops, produces, and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for life sciences and materials research, as well as medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.

With a portfolio aligned with future growth areas like digitalization, healthcare and Industry 4.0 as well as a strong brand, ZEISS is shaping technological progress and, through its solutions, is extending the horizon of the world of optics and associated areas. ZEISS' significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 14% of its revenue in research and development work – ZEISS has a long tradition of high expenditure in these areas. This also represents the company's investment in the future.

With more than 46,555 employees, ZEISS operates in around 50 countries with more than 60 sales and service sites, 40 research and development sites and 35 production sites worldwide (as of 31 March 2025). The headquarters of the company, which was founded in Jena in 1846, is located in Oberkochen, Germany. The Carl Zeiss Foundation, one of Germany’s largest foundations committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG.

Further information at www.zeiss.com

ZEISS Research Microscopy Solutions

ZEISS Research Microscopy Solutions is the leading provider of light, electron, X-ray microscope systems, correlative microscopy and software solutions leveraging AI technologies. The portfolio comprises of products and services for life sciences, materials and industrial research, as well as education and clinical routine applications. The unit is headquartered in Jena. Additional production and development sites are located in Germany, UK, USA, China and Switzerland. ZEISS Research Microscopy Solutions is part of the Industrial Quality & Research segment.

Further information at www.zeiss.com/microscopy